Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection


Despite an available vaccine and efficient treatment for hepatitis B virus ( HBV ) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradica tion possible. Most important, vaccination must be scaled- up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority .

access to prophylaxis and treatment , Hepatitis B , linkage to care , screen-and-treat-programs

About Speaker

Michael MANNS


City: Hannover

Institution: Hannover Medical School

Biography of Michael MANNS

Michael P. Manns is Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (MHH), Hannover,
Germany since 1991. Since 2015 he is also Clinical Director of the Helmholtz Centre for Infection Research (HZI), Braunschweig, and Founding Director of the Centre for Individualised Infection Medicine (CIIM), Hannover.

He graduated in medicine from the University of Vienna in Austria and the University of Mainz in Germany before completing postgraduate training at the Free University of Berlin, Germany, and the University of Mainz, where he became Professor of Medicine in 1986. Subsequently, Professor Manns was a Research Associate at the Scripps Research Institute in La Jolla, California, USA, from 1987 to 1988.

Professor Manns is founder and Chairman of Hep-Net, a national network of competence on viral hepatitis, and the German Liver Foundation. He has been President of the German Society of Gastroenterology (DGVS), the German Association for the Study of the Liver (GASL), the German Society of Internal Medicine (DGIM) and United European Gastro­enterology (UEG).

Since 2015 Prof. Manns is member of the Scientific Panel for Health (SPH) of the European Commission. Professor Manns has received numerous awards including the International Hans Popper Award in 1995 and the European Association for the Study of the Liver (EASL) Recognition Award in 2007.

Professor Manns has a long-term research interest in liver diseases with a main focus on viral hepatitis, autoimmune liver diseases, hepatocellular
carcinoma, liver transplantation and regenerative medicine.

He has published more than 1000 articles in international peer-reviewed journals such as the New England Journal of Medicine, The Lancet, Nature,
Nature Medicine, Cell, Gastroenterology, and Hepatology among others. He has an h-index of 153 (as of May 8, 2018). According to Thomson Reuters he ranks among the top 1 % of most cited researchers in clinical medicine.

View more